San Mateo‑based SiFive closed a $400 million Series G, led by Atreides Management, cementing its push to commercialise open‑standard RISC‑V chips that rival Arm’s proprietary designs. The funding will finance product scaling and, according to CEO Patrick Little, likely represents the last private round before the company seeks an IPO, in the chip market. Investors view the raise as validation of the open‑source silicon model.

El Segundo’s Hermeus secured $200 million in equity and an additional $150 million of debt, pushing its valuation to $1 billion as it develops the fastest unmanned defense aircraft. Biotech players Sidewinder Therapeutics and Stipple Bio each raised over $100 million to advance antibody‑drug conjugates and precision cancer therapies, while Aria Networks pulled in $125 million to scale its AI‑driven data‑center optimization platform for next‑gen platforms.

Starfish Space added $111.7 million to fund autonomous on‑orbit servicing vehicles that can refuel, reposition or de‑orbit satellites, addressing growing debris concerns. Endovascular Engineering’s $80 million Series C backed its FDA‑cleared Hēlo device for venous thromboembolism, while Life Biosciences raised $80 million to push cellular‑rejuvenation therapy ER‑100 toward human trials. Collectively, the week’s megadeals underscore deep investor confidence in hardware‑intensive and life‑science innovations across multiple sectors.